Reviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC Wainwright

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

Shares of RVPH stock opened at $3.06 on Monday. The stock has a market cap of $85.44 million, a P/E ratio of -1.87 and a beta of -0.02. Reviva Pharmaceuticals has a one year low of $2.67 and a one year high of $9.25. The stock has a fifty day moving average price of $3.60 and a 200 day moving average price of $4.11.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RVPH. Armistice Capital LLC raised its stake in Reviva Pharmaceuticals by 194.0% during the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after acquiring an additional 1,164,000 shares in the last quarter. EMC Capital Management raised its stake in Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock worth $613,000 after acquiring an additional 115,028 shares in the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in Reviva Pharmaceuticals during the fourth quarter worth $72,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.